Information Journal Paper
APA:
Copy. (2017). Interim data from the first clinical study of ADCT‐ 301, a novel pyrrplomenzodiaza-pine based antibody drug conjugate, in relapsed/refractory hodgkin/non-hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY, 35(S2), 270-271. SID. https://sid.ir/paper/747521/en
Vancouver:
Copy. Interim data from the first clinical study of ADCT‐ 301, a novel pyrrplomenzodiaza-pine based antibody drug conjugate, in relapsed/refractory hodgkin/non-hodgkin lymphoma. HEMATOLOGICAL ONCOLOGY[Internet]. 2017;35(S2):270-271. Available from: https://sid.ir/paper/747521/en
IEEE:
Copy, “Interim data from the first clinical study of ADCT‐ 301, a novel pyrrplomenzodiaza-pine based antibody drug conjugate, in relapsed/refractory hodgkin/non-hodgkin lymphoma,” HEMATOLOGICAL ONCOLOGY, vol. 35, no. S2, pp. 270–271, 2017, [Online]. Available: https://sid.ir/paper/747521/en